Drug intelligence / Profile preview

FL-101

Development stage: Unknown
Lead developer: 1ST Biotherapeutics
Modality: Small Molecules
Administration: Oral

Overview

FL-101 is an early-stage oncology drug candidate currently in the discovery phase, developed by First Biotherapeutics (also known as 1ST Biotherapeutics). As of early 2024, the specific molecular target and mechanism of action for FL-101 remain undisclosed by the company. The program is part of First Biotherapeutics' oncology portfolio, which leverages the company's specialized platform for small molecule drug discovery to identify first-in-class therapeutics. FL-101 is being developed alongside other oncology assets such as FB849 (an HPK1 inhibitor) and 1ST-206 (a GCN2 inhibitor), representing the company's expansion into the immuno-oncology and precision medicine space.

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)

Beyond the preview

Go deeper on FL-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL-101.

Explore the full profile